Resilient Performance Amid Macroeconomic Challenges
Ashland maintained strong margins and achieved revenue and EBITDA in line with expectations despite ongoing macroeconomic challenges. Adjusted EBITDA was $119 million, marking a 5% increase on a comparable basis.
Life Sciences and Personal Care Success
Life Sciences saw continued demand for high-value cellulosic excipients, tablet coatings, and injectables. Personal Care generated broad-based gains with strong volume growth, outperforming a muted market environment.
Manufacturing Optimization Initiative
The $60 million manufacturing optimization program is underway, with $5 million in savings this year and $18 million projected next year, aiding margin improvements.
Strong Adjusted EBITDA Margins
Adjusted EBITDA margin expanded to 24.9%, up 110 basis points from last year, marking the most profitable quarter of the year.
Steady Cash Generation and Improved Liquidity
Ongoing free cash flow totaled $52 million with total liquidity standing at just over $800 million. A $103 million tax refund improved net leverage to closer to mid-2s.